KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash from Financing Activities (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Cash from Financing Activities for 8 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 17.74% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, down 13.74% year-over-year, with the annual reading at $3.8 million for FY2025, 13.74% down from the prior year.
  • Cash from Financing Activities hit $1.0 million in Q4 2025 for Vir Biotechnology, up from $102000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $87.5 million in Q1 2021 to a low of $31000.0 in Q3 2024.
  • Historically, Cash from Financing Activities has averaged $7.5 million across 5 years, with a median of $2.0 million in 2022.
  • Biggest YoY gain for Cash from Financing Activities was 102844.71% in 2021; the steepest drop was 98.88% in 2021.
  • Year by year, Cash from Financing Activities stood at $5.7 million in 2021, then tumbled by 64.53% to $2.0 million in 2022, then decreased by 16.46% to $1.7 million in 2023, then fell by 24.82% to $1.3 million in 2024, then dropped by 17.74% to $1.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for VIR at $1.0 million in Q4 2025, $102000.0 in Q3 2025, and $2.0 million in Q2 2025.